Pancytopenia and marrow infiltration: Viva

This is a branching oral built to probe the reasoning that holds the empty-versus-full marrow distinction at the centre, and to expose the candidate who has memorised the headline without the corners. The questions escalate from the framing to the stabilisation, the diagnosis, and the definitive management, with deliberate probes into the pitfalls. [3]

Opening question: framing the problem

The examiner opens with the film and the count and asks: how do you frame this problem in a single sentence, and what is your first priority? [1]

A strong answer names pancytopenia, the fall in all three lineages, and states that the first decision is whether the marrow is empty (failure) or full (infiltration). The circulating blasts with organomegaly settle the direction here: this is a marrow malignancy until proven otherwise. The first priority is the resuscitation of the unstable elements, because a child with a haemoglobin of 62, a neutrophil count of 0.4, and a fever is at risk of bleeding, infection, and the oncologic emergencies. [12]

Model answer. This child has pancytopenia with circulating blasts, which is acute leukaemia with marrow infiltration until proven otherwise. My first priority is to resuscitate the dangerous elements, the anaemia, the bleeding risk, the neutropenic fever, and the tumour lysis risk, and then to confirm the diagnosis with an urgent bone marrow aspirate and trephine biopsy in a specialist centre. [3]

Probe one: the resuscitation

The examiner presses: tell me exactly what you do in the first four hours, and why you choose those blood products. [12]

A strong answer reproduces the three legs. Red cells are transfused for symptomatic or rapidly falling anaemia, given slowly, and all cellular products are irradiated and leucodepleted to prevent transfusion-associated graft-versus-host disease in the immunocompromised child. Platelets are held for a count under ten times ten to the nine per litre in the stable child and under twenty in the febrile or bleeding child. Tumour lysis is prevented with hyperhydration using an isotonic fluid without potassium, rasburicase for the high-risk child, and four-to-six-hourly biochemistry. The febrile neutropenia gets an empiric antipseudomonal beta-lactam within one hour after blood cultures. [12]

Pitfall probe. Why must you check the glucose-6-phosphate dehydrogenase status before giving rasburicase? Because rasburicase causes severe haemolysis and methaemoglobinaemia in the deficiency, and an alternative such as allopurinol is used where the status is unknown in an at-risk child. [12]

Probe two: the diagnostic pathway

The examiner asks: how do you confirm the diagnosis, and what ancillary studies do you send on the marrow, and why? [3]

A strong answer describes the bone marrow aspirate and trephine biopsy at the posterior iliac crest, with the aspirate providing cells for morphology, flow cytometry to define the lymphoid lineage, and the molecular studies, and the trephine biopsy providing the architecture and the cellularity. The cytogenetics and the molecular panel, including the fusion transcripts and the copy-number changes, drive the risk stratification that shapes the protocol, and the minimal residual disease at the end of induction is the key determinant of the intensity that follows. [3]

Pitfall probe. What would a leucoerythroblastic film with teardrop poikilocytes and nucleated red cells tell you instead of blasts? It would point to marrow infiltration, fibrosis or myelophthisis, the picture of a replaced marrow rather than a sheet of blasts, and it would redirect the search to the solid tumours, the histiocytic disorders, and the fibrotic and granulomatous processes. [11]

Branch one: the Down syndrome neonate

The examiner pivots: imagine instead a two-week-old with Down syndrome and a white cell count of 60 with circulating blasts. What is this, and what is its natural history? [6]

A strong answer names the transient myeloproliferative disorder, driven by a truncating GATA1 mutation, affecting roughly one in ten neonates with trisomy 21, resolving spontaneously in most, but carrying a risk of hepatic fibrosis in the minority and of acute megakaryoblastic leukaemia in roughly ten to twenty percent of survivors within the first few years. Every affected neonate enters a surveillance programme. The pitfall is to over-treat the transient disorder as leukaemia or to lapse the surveillance and miss the later leukaemia. [6]

Branch two: the empty marrow

The examiner pivots again: imagine instead a child with the same count but a hypocellular marrow with fat replacement and no clone, and no organomegaly. What is this, and how is it defined and treated? [10]

A strong answer names severe acquired aplastic anaemia, defined by the Camitta criteria, a markedly hypocellular marrow with at least two of a neutrophil count under 0.5, platelets under 20, and a corrected reticulocyte count under one percent. The first-line treatment is allogeneic haematopoietic stem cell transplant when a matched sibling donor is available, and immunosuppressive therapy with horse antithymocyte globulin at 40 mg per kg per day for four days and ciclosporin at 5 mg per kg per day when no donor is available. The inherited marrow failure syndromes are sought and excluded before the label acquired is applied, because they change the conditioning regimen and the surveillance. [10]

Branch three: the sudden reticulocytopenia

The examiner pivots once more: imagine a child with hereditary spherocytosis and a sudden fall in haemoglobin to 42 with a reticulocyte count of 0.1 percent after a viral illness. What is this, and how is it treated? [9]

A strong answer names parvovirus B19 transient pure red cell aplasia, in which the virus targets the red cell precursor through the blood group P antigen and shuts down red cell production, producing an aplastic crisis in the child whose red cell lifespan is already short. It is self-limiting in the immunocompetent child, treated supportively with transfusion, and the immunocompromised child is treated with intravenous immunoglobulin at 400 mg per kg per day for five to ten days and the reduction of immunosuppression. [9]

Closing question: counselling the family

The examiner closes: the diagnosis of acute lymphoblastic leukaemia is confirmed. How do you counsel the family? [3]

A strong answer describes the honest and hopeful conversation that names the diagnosis, explains that it is the commonest childhood cancer, that the contemporary survival exceeds ninety percent on the modern protocols, and that the treatment runs over two to three years through the phases of induction, consolidation and maintenance. The family is introduced to the multidisciplinary team, given a written plan, taught the neutropenic precautions and the fever emergency, and supported by the social work and the educational liaison. The fellow who can hold the science and the humanity together in this conversation demonstrates the reasoning the boards reward. [3]